Investment Knowledge Center

  The U.S. Federal Reserve’s recent decision to cut its benchmark interest rate by 0.25% to a range of 4.25%–4.50% has sent ripples through global financial markets. While the move was widely expected, the Fed’s unexpected projection of fewer rate cuts in 2025 unsettled investors, triggering a sharp sell-off in equities worldwide. In its latest economic outlook, the Fed reduced its expected number of quarter-point cuts in 2025 from four to just two, indicating that higher interest rates may persist longer than previously anticipated. This shift has amplified concerns about the pace of global economic recovery. Fed Chair Jerome Powell noted that inflation has "eased significantly" but remains "somewhat elevated" compared to the central bank’s 2% target. Despite optimism about the U.S. economy, Powell emphasized the Fed is nearing the end of its current rate-cutting cycle. Global Market Reactions Wall Street reacted sharply to the Fed’s announcement, with all ...

 

  The US House of Representatives has made a groundbreaking move by passing the BIOSECURE Act, restricting drug companies from collaborating with specific Chinese biotech for the next eight years. Approved with a decisive 306-81 vote, the legislation is set to reshape global pharmaceutical sourcing strategies. While it presents promising opportunities for Indian pharmaceutical players, significant challenges lie ahead. What Is the BIOSECURE Act? The BIOSECURE Act aims to reduce dependency on Chinese pharmaceutical suppliers by barring select Chinese firms from receiving US government contracts or grants. Companies like BGI Genomics, MGI Tech, Complete Genomics, WuXi AppTec, and WuXi Biologics are explicitly named in the bill. Although awaiting Senate approval, the act has already created ripples across the global pharma industry. Opportunities for Indian Pharma As the US diversifies its pharmaceutical supply chain, Indian companies such as Laurus Labs, Syngene International, Pirama...